Yang Zhengyan, holds a PhD degree. She is an associate professor in the Department of Pathology at the Medical College of Henan University, a member of the Henan Provincial International Joint Laboratory for Nuclear Protein Gene Regulation, a master's supervisor, a member of the Medical Ethics Committee of the Henan Provincial Anti-Cancer Association, and a young executive member of the Molecular Oncology Committee of the Henan Provincial Anti-Cancer Association. Her research focuses on tumor pharmacology, primarily exploring the transformation mechanisms of tumor stem cells, screening of anti-tumor drugs, and identification of new targets.
Henan Provincial Department of education, the key R & D and promotion special project of science and technology in Henan Province in 2023, 232102311205, High throughput identification and effect evaluation of hsf1-stat3 dual target traditional Chinese medicine monomers, 2023-01 to 2024-12, conclusion, presided over
National Natural Science Foundation of China, Youth Science Foundation project, 81803575, the role and molecular mechanism of methidatazine in reversing Herceptin resistance in gastric cancer, 2019-01-01 to 2021-12-31, conclusion, presided over
Henan Provincial Department of education, key scientific research projects of colleges and universities in Henan Province, 19a310006, study on the role and mechanism of methidatazine in reversing tumor drug resistance, 2019-01 to 2020-12, conclusion, presided over
DRD4 promotes chemo-resistance and cancer stem cell-like phenotypes by mediating the activation of the Akt/β-catenin signaling axis in liver cancer. British Journal of Cancer. 2024, 131(7): 1212-1223.
Comprehensive analysis of the lncRNAs-related immune gene signatures and their correlation with immunotherapy in lung adenocarcinoma. British journal of cancer. 2023, 129(9):1397-1408.
Synthesis and Evaluation of Naphthalene Derivatives as Potent STAT3 inhibitors and Agents Against Triple Negative Breast Cancer Growth and Metastasis, Breast cancer research and treatment, 2023, 197(2): 255-267.
Thioridazine reverses trastuzumab resistance in gastric cancer by inhibiting S-phase kinase associated protein 2-mediated aerobic glycolysis. World Journal of Gastroenterology, 2023;29(45): 5974-5987.
beta2-AR signaling controls trastuzumab resistance-dependent pathway，Oncogene, 2016, 35(1): 47-58.
Application of dihydroergot mesylate targeting STAT3 in the preparation of anti-inflammatory diseases and antitumor drugs, patent number: ZL202211141779.X
A class of naphthylurea compounds with anticancer effect and its preparation method and application. The authorized patent number is: ZL202110727896.3
Synthesis and preparation methods of a class of curcumin derivatives and their application in cancer treatment, patent number: ZL201911333226.2
1. The first prize of the 20th Kaifeng Natural Science excellent academic achievement award;
2. The second prize of excellent scientific and Technological Paper Award of Henan Provincial Department of education in 2024;
3. The second prize of excellent scientific and Technological Paper Award of Henan Provincial Department of education in 2023;
4. The second prize of the 19th Kaifeng Natural Science excellent academic achievement award;
5. In 2022, he won the first prize of the undergraduate creative group in the Henan "Internet +" undergraduate innovation and entrepreneurship competition, Jingguo biology, an explorer of high-yield paclitaxel based on Chlorella biosynthesis technology, and an excellent instructor.
